<DOC>
	<DOCNO>NCT00656058</DOCNO>
	<brief_summary>Background : Bronchiolitis obliterans form chronic graft-versus-host disease ( GVHD ) sometimes develops stem cell transplantation ( SCT ) bone marrow transplantation ( BMT ) . In bronchiolitis obliterans , immune cell normally fight infection attack lung transplant recipient , cause destruction lung tissue fibrosis ( scar ) . When fibrosis develop , lung work properly . Montelukast ( Singulair ) drug use many year treat asthma . Its use treatment bronchiolitis obliterans experimental . Objectives : To see montelukast improves stabilize lung function patient develop bronchiolitis obliterans BMT SCT . To assess safety montelukast patient bronchiolitis obliterans BMT SCT To see montelukast affect cell damage lung . To see montelukast improves form chronic GVHD , quality life , overall survival patient bronchiolitis obliterans BMT SCT . Eligibility : Patients 6 year age old bronchiolitis obliterans follow stem cell transplantation . Design : Patients take one montelukast tablet daily 6 month undergo follow procedure period : - Lung function test . The patient breathes machine measure amount air go lung . This test do month 3 month , 6 month , 12 month 24 month . - Medical history physical examination study site every 3 month first year study 12 month 24 month . Patients also physical examination monthly first 6 month primary doctor office . Tests may include blood urine test , chest compute tomography ( CT ) scan , echocardiogram ( heart ultrasound ) , 2- 6-minute walk test , quality-of-life questionnaire . - Bronchoalveolar lavage patient 18 year age old . The subject mouth , nose airway numb lidocaine . Some patient may need sedation anesthesia procedure . A tube ( bronchoscope ) pass nose airway , small amount fluid put lung . The fluid remove tested infection lung problem . - Apheresis collect white blood cell . Whole blood collect tube insert vein arm . The white cell extract cell separator machine , rest blood return body tube place vein arm . The cell use study GVHD bronchiolitis obliterans . - Patients wish continue montelukast therapy 6 month may care primary doctor , agree continuation ... .</brief_summary>
	<brief_title>Montelukast Treat Bronchiolitis Obliterans</brief_title>
	<detailed_description>Background : Bronchiolitis obliterans ( BO ) insidious disease high mortality follow allogeneic blood marrow transplantation ( BMT ) . There consistently effective treatment BO follow BMT pathogenesis largely unknown . The mechanism underlie similar immune-mediated lung destructive process well elucidate . Rejection follow allogeneic lung transplantation scleroderma lung disease result analogous immunologically mediate destruction lung tissue lead similar pathologic clinical presentation post-BMT BO . Increased leukotriene production recently implicate development post-lung transplant BO scleroderma lung disease animal model patient study . Montelukast ( singulair ) approve , well-tolerated , oral agent inhibits leukotriene action lung inflammation . This agent extensively use child adult treat asthma excellent safety profile . Objectives : To evaluate montelukast stabilizes improves pulmonary function patient BO BMT use forced expiratory volume 1 ( FEV-1 ) change primary endpoint , oxygen saturation , pulmonary function test ( PFT ) parameter ( forced expiratory flow ( FEF ) 25-75 , residual volume ( RV ) RV/forced vital capacity ( FVC ) , carbon monoxide diffuse capacity ( DLC02 ) , FEV-1/FVC , FEV-1/slow vital capacity ( SVC ) ratio ) , time walk test secondary endpoint . To evaluate safety montelukast population patient BO BMT . To investigate leukotriene elevation contributes pathogenesis BO BMT measure leukotriene level blood , urine , bronchoalveolar lavage ( BAL ) , leukotriene surface receptor expression immune cell montelukast administration . To determine montelukast improve chronic graft versus host disease ( cGVHD ) manifestation , quality life , overall survival . Eligibility : Patients great equal 6 year old bronchiolitis obliterans follow stem cell transplantation disease indication may enrol . Design : This prospective phase II study , primary aim ass whether montelukast improve stabilizes pulmonary function patient BO BMT . Primary outcome data analyze 2 way . 1 ) The proportion patient stable improved percent predict FEV-1 compare benchmark data obtain literature review . 2 ) The slope FEV-1 introduction montelukast compare . Pediatric adult patient BO follow BMT receive approve dos montelukast continuously . The planned length study would 2 year per patient primary endpoint 6 month , permit sufficient time determine safety meet endpoint . This phase II trial conduct 2 institution : National Institutes Health ( NIH ) Fred Hutchinson Cancer Research Center . Forty-five patient enrol trial .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Bronchiolitis</mesh_term>
	<mesh_term>Bronchiolitis Obliterans</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>INCLUSION CRITERIA : Age great 6 year old . Diagnosis bronchiolitis obliterans allogeneic autologous stem cell transplant . The criterion base definition create National Institutes Health ( NIH ) consortium chronic graft versus host disease ( cGVHD ) . As part criterion , patient without pathologic evidence BO , one sign chronic GVHD must present . For diagnosis cGVHD , minimum follow must present : 1 ) process distinct diagnose acute GVHD , 2 ) presence diagnostic sign distinctive sign support another clinical laboratory test , 3 ) exclusion pathology ( i.e . recurrent cancer , drug reaction infection ( see Appendix 5a list diagnostic signs. ) . To meet criterion diagnosis bronchiolitis obliterans , patient must fulfill 3 criterion . Prior lung tissue biopsy analyze confirm show evidence bronchiolitis obliterans National Cancer Institute ( NCI ) Laboratory Pathology available . If tissue available confirmation , new biopsy perform . For bronchiolitis obliterans : 1 . Forced expiratory volume 1 ( FEV1 ) less equal 75 percent predict pulmonary function evaluation height weight . 2 . Evidence airtrapping small airway thicken bronchiectasis high resolution chest compute tomography ( CT ) residual volume ( RV ) RV/forced vital capacity ( FVC ) great 120 percent evidence chronic GVHD another organ , OR FEV1/ vital capacity ( slow force VC whichever large ) ratio le 5 percent predict age less 0.7 , OR pathologic evidence bronchiolar inflammation obstruction lumen consistent diagnosis BO . Pulmonary function test utilize body plethysmography helium study pertinent value discrepancy available . 3 . Absence active infection appropriate investigation clinical symptom include radiographic , microbiologic , pathologic study determine PI LAI . Patients must also 2 PFT measurement document FEV1 value great 3 month apart calculate entry FEV1 slope . All available prior PFTs utilized baseline slope calculation . For adult patient , absolute FEV1 utilize slope calculation ; pediatric patient , percent predict use . For patient enrol acute decline follow BMT without 2 postBMT value great 3 month apart , preBMT value may utilize first value entry PFT value may second slope calculation . The baseline 6thcycle PFT do accrue site . Prior therapy : For patient chronic diagnosis BO treatment , prior therapy administer chronically &gt; 3 month acceptable enrollment long patient demonstrate consistent improvement attribute agent one month ( ) period observation precede enrollment . For patient steroid , steroid burst exceed increase one half mg/kg/day consider start 3 month monitoring period . Notably , document intercurrent infection treat antimicrobial result improvement , previous baseline consider improvement attributable immunosuppressive therapy . Patients consistent improvement month precede trial entry eligible since way discern improvement due montelukast versus another therapy . Alternatively , patient new diagnosis bronchiolitis obliterans characterize new decrease FEV1 also eligible study . Notably , patient receive bronchodilator pulmonary therapy may include study long montelukast part regimen . Performance status : Karnofsky Lansky performance status great equal 40 percent ( Appendix 1 ) . Ability give inform consent . For patient le 18 year age , legal guardian must give informed consent . Pediatric patient include age appropriate discussion accordance NIH guideline participate institutional guideline . Hepatic function : Patients must evidence adequate liver function prior enrollment define total bilirubin le 3 time upper limit normal transaminase le 5 time upper limit normal age appropriate index . Cardiac function : Patients must evidence adequate cardiac function prior enrollment define ejection fraction great 25 percent perform within last 6 month NIH absence symptom cardiac disease FHCRC , JHH , Hackensack . Pulmonary function : Patients must FEV1 great equal 20 percent predict inclusion study . EXCLUSION CRITERIA : Underlying disease status : Patients tumor burden great minimal residual disease ( i.e . tumor burden detect molecular method ) would exclude study . Prior posttransplant treatment montelukast zakirlukast within past 2 month total duration therapy exceed 3 month . Clinically significant systemic illness manifestation significant organ dysfunction judgment Principal Associate Investigator would render patient unlikely tolerate protocol therapy complete study . Patients must current cGVHD therapeutic regimen least 3 month stable decrease FEV1 eligible trial . Any patient therapy le 3 month cGVHD need monitor 3 month without improvement FEV1 prior enrollment . Ventilated patient exclude . Patients take rifampin phenobarbital medication alter metabolism montelukast . Patients take great one ageappropriate dose ibuprofen aspirin contain product per day inhibit cyclooxygenase exclude trial . The acceptable upper limit adult daily dose aspirin 650mg/day 800mg/day ibuprophen . For child , acceptable upper limit ibuprophen pediatric dose per day ( less 10 mg per kg maximum 800 mg ) . Children take aspirin due risk Reye 's syndrome unless specifically prescribed physician . Patients history allergy montelukast . Pregnant female nurse mother exclude trial due unknown risk develop fetus . While study , patient childbearing potential must able consent utilize effective birth control measure .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Leukotriene</keyword>
	<keyword>Chronic Graft-Versus-Host Disease</keyword>
	<keyword>Montelukast</keyword>
	<keyword>Stem Cell Transplant</keyword>
	<keyword>Bronchiolitis Obliterans</keyword>
</DOC>